InvestorsHub Logo
Followers 21
Posts 980
Boards Moderated 0
Alias Born 03/20/2019

Re: louieblouie post# 312595

Tuesday, 12/01/2020 10:51:41 AM

Tuesday, December 01, 2020 10:51:41 AM

Post# of 426504
Filing the lawsuit was a great move. It likely puts other generics at bay and you're right it backs Hikma into a corner. Do you knowingly put more product into the market greater than the Marine indication when it's likely that you will be the only generic now trying to compete with Amarin in the USA. Other generics can see this has escalated beyond a headache given lost profit damages.

Then there's the lack of CV limitation in the Indication and Usages section of the labeling that is glaring.

For the generics this is no longer low hanging fruit but rather the potential for real harm to their underlying business if they are liable. You can find out a lot in discovery. Hikma's actions post the GSK v. Teva ruling to try to take down press releases and alter its website are telling.

Hikma may have thought other generics would be joining them at the buffet...come to find out it's just them and Amarin and there ain't much food to be had for the cost of admission.

Great move on Amarin's part. What's your move Hikma......
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News